If you take fish oil hoping it will keep your skeleton strong, one of the largest randomized trials ever run on the question has some unwelcome news. In a study of 25,871 generally healthy adults, marine omega-3 supplements did not lower the risk of fractures. The one bone-density bump researchers found was tiny and showed up in only one measurement.
The results come from an ancillary study of the VITamin D and OmegA-3 TriaL (VITAL), published in the Journal of Bone and Mineral Research in 2026.
The Hype: Why Fish Oil Seemed Like a Bone Booster
The idea was not unreasonable. The authors note that preclinical studies suggest omega-3 fatty acids may benefit skeletal health. That kind of animal and lab evidence is encouraging, but it often fails to carry over to people. The paper also points out that few randomized controlled trials had tested supplemental omega-3 on bone outcomes in humans. This study was designed to fill that gap.
How the Trial Worked
VITAL was a 2 × 2 factorial, randomized, placebo-controlled trial. It tested marine omega-3 fatty acids, vitamin D3, both, or placebo. Its original purpose was to look at cancer and cardiovascular events. The bone analysis was an ancillary study.
Key design details:
- Dose: 1 gram per day of marine omega-3, with EPA and DHA in a 1.2:1 ratio
- Participants: 25,871 U.S. men aged 50 or older and women aged 55 or older
- Exclusions: People with cancer or cardiovascular disease at baseline were not enrolled
- Selection: Participants were not chosen for low bone density or prior fracture
- Timeline: The intervention ran from November 2011 through December 2017, with a median follow-up of 5.3 years
- Average age: 67.1 years
The primary outcomes were adjudicated incident total, nonvertebral, and hip fractures across the whole cohort. In a smaller subcohort of 771 people, researchers also measured two-year changes in bone density and structure. They used DXA for areal bone mineral density (aBMD). They used peripheral quantitative CT for volumetric BMD, cortical thickness, and bone strength indices at the radius and tibia.
The Fracture Results: Basically Nothing
Omega-3 did not reduce fractures of any type that was measured:
- Total fractures: HR 1.02 (95% CI 0.92–1.13; p = .73)
- Nonvertebral fractures: HR 1.01 (95% CI 0.91–1.12; p = .80)
- Hip fractures: HR 0.89 (95% CI 0.61–1.30; p = .55)
A hazard ratio of 1.0 means no difference between groups. The total and nonvertebral figures sit almost exactly there. The hip fracture estimate is lower at 0.89, but its confidence interval runs from 0.61 to 1.30 and the p-value is .55. That is consistent with no effect, and the study does not support claiming a hip benefit.
The Bone Density Results: One Tiny Blip
In the 771-person subcohort, whole-body aBMD changed by +0.03% in the omega-3 group versus −0.41% in the placebo group (p = .006). The authors describe this as a small increase.
Everything else came up empty. There was no effect on aBMD at the spine or hip. There was no effect on volumetric BMD or on bone strength indices at the radius or tibia. A small whole-body change with no matching improvement at the sites that matter most for fractures is hard to read as meaningful protection. This subcohort also tested several measurements, so one isolated positive among many nulls should be treated cautiously.
Was It Safe?
No serious adverse effects were observed. So the finding is not that fish oil harmed bones. It simply did not help them in this population.
What This Means for You
Who the findings apply to: Generally healthy, community-dwelling midlife and older adults, not selected for low bone density or fracture history. The trial cannot say whether omega-3 helps people with osteoporosis, people at very high fracture risk, or those with other conditions. It also tested one dose and formulation, 1 g/day of EPA plus DHA, so other doses are untested here.
Practical takeaways:
- Do not rely on fish oil as a bone strategy. In this trial, 1 g/day over a median of 5.3 years did not reduce total, nonvertebral, or hip fractures.
- Don't expect a density boost. The only change was a small whole-body difference, with no benefit at the spine, hip, radius, or tibia.
- Timing is not a fix. The trial used a daily supplement and found no fracture benefit, so there is no evidence that a particular time of day would change the result.
- If you already take it for other reasons, this study gives no sign of bone harm. Omega-3 has been studied for other health purposes, and those questions are outside this paper. Talk to your clinician about whether it suits your overall situation.
- If bone health is your concern, ask your doctor about approaches with stronger evidence. What those are falls outside this paper's scope.
Caveats Worth Knowing
The bone density measurements covered only two years in 771 people, so that part of the study is smaller and shorter than the fracture analysis. The participants were generally healthy and not selected for bone risk, which limits what the trial can say about higher-risk groups. The disclosure statement lists one author as having other financial or material support from Pharmavite.
The Bottom Line
The animal and lab rationale for omega-3 and bone was plausible. In humans, a very large, rigorous trial did not deliver. The authors conclude that marine omega-3 supplementation did not reduce incident fracture risk and had no other effects on BMD or bone strength measures compared with placebo, apart from a small whole-body aBMD increase. For bone protection, fish oil does not appear to be the answer.